Hypothesis: The severity of hearing loss (HL) associated with vestibular schwannomas (VSs) is influenced by genes expressed by the VSs. Background: Hearing loss is the most common presenting symptoms in patients with VSs, yet its pathophysiology remains elusive. Previous studies have suggested that VSs cause HL not only by inducing degeneration of the auditory nerve by compression but also by promoting degeneration of the inner ear. This study aimed to determine whether there is a molecular basis for differences in HL associated with VSs. Methods: Surgical specimens of VSs were collected from 13 patients and were divided into a group associated with good (word recognition 970% and pure-tone average e30 dB) or poor hearing. Whole-genome expression profiling of VSs was performed with the Affymetrix GeneChip Human X3P Array. The expression of select genes was validated using real-time quantitative reverse transcriptionYpolymerase chain reaction and immunohistochemistry. Because of a small sample size, exact nonparametric tests were used to assess the association between good versus poor hearing and specific histological features of the tumors and patient demographics.
Hypothesis: The severity of hearing loss (HL) associated with vestibular schwannomas (VSs) is influenced by genes expressed by the VSs. Background: Hearing loss is the most common presenting symptoms in patients with VSs, yet its pathophysiology remains elusive. Previous studies have suggested that VSs cause HL not only by inducing degeneration of the auditory nerve by compression but also by promoting degeneration of the inner ear. This study aimed to determine whether there is a molecular basis for differences in HL associated with VSs. Methods: Surgical specimens of VSs were collected from 13 patients and were divided into a group associated with good (word recognition 970% and pure-tone average e30 dB) or poor hearing. Whole-genome expression profiling of VSs was performed with the Affymetrix GeneChip Human X3P Array. The expression of select genes was validated using real-time quantitative reverse transcriptionYpolymerase chain reaction and immunohistochemistry. Because of a small sample size, exact nonparametric tests were used to assess the association between good versus poor hearing and specific histological features of the tumors and patient demographics. Results: Using gene set enrichment analysis, the chromosomal region 3q27 was found to be significantly different between the 2 groups of tumors. This region includes peroxisomal biogenesis factor 5Ylike gene, which was underexpressed in VSs with poor hearing. The expression of 3 other genes from different chromosomes was significantly different between the 2 groups: RAD54B, prostate-specific membrane antigenYlike, and carcinoembryonic antigen. Conclusion: This study identified several molecular alterations in VSs stratified by hearing. These alterations may determine the severity of HL associated with VSs and may represent potential therapeutic targets to prevent or reduce HL in theses patients. Key Words: Carcinoembryonic antigenVHearing lossVPeroxisomal biogenesis factor 5YlikeVPlatelet factor 4VProstate-specific membrane antigenYlikeVRAD54BVVes-tibular schwannoma. Otol Neurotol 30:661Y667, 2009. Vestibular schwannomas (VSs), also known as acoustic neuromas, typically arise from Schwann cell of the vestibular nerves, yet most commonly cause hearing loss (HL) rather than vestibular dysfunction. The pathophysiology of the progressive sensorineural HL associated with VSs is uncertain and current treatment is inadequate. Yet, HL markedly decreases the quality of life and social functioning of affected patients. Understanding the elusive pathophysiology of the HL associated with VSs was the main objective of this study.
Previous studies have suggested that VSs cause HL not only by inducing degeneration of the auditory nerve (1,2) but also by promoting degeneration of the inner ear (3, 4) , possibly by secreting a toxic substance or substances. An alternative explanation is that VSs induce a change in the microenvironment, resulting in a deficiency in a factor that is important for normal nerve or receptor function. In an attempt to explore these hypotheses and identify genetic determinants of HL associated with VSs, we have undertaken wholegenome expression profiling of VSs stratified by hearing. Although high-throughput microarray technology has been used to study VSs tumorigenesis (5, 6) , this is the first study that uses this technology to elucidate mechanisms of HL associated with VSs.
MATERIALS AND METHODS

Study Population and Tissue Collection
Surgical specimens of VSs from 13 adult, nonsmoking patients who underwent surgical resection at the Massachusetts General Hospital were received from the hospital's neurooncology tumor bank. The specimens were handled according to the institutional review board's study protocol approved by the Human Studies Committee of the Massachusetts General Hospital (Protocol No. 2004-P-2297/2, PI: A.O.S.-R.) and the Massachusetts Eye and Ear Infirmary (Protocol No. 05-02-009X, PI: J.B.N.). The tumors were divided into a group with good hearing (word recognition 970% and pure-tone average (PTA) e30 dB) or poor hearing. All patients had good hearing in the contralateral ear to reduce the likelihood of an underlying degenerative or systemic disease that may contribute to HL. Patient demographics are summarized in Table 1 . Immediately upon harvest, the specimens were stored at j80-C until the time of ribonucleic acid (RNA) extraction. Whole-genome expression profiling of VSs was performed with the GeneChip Human X3P Array (Affymetrix, Santa Clara, CA, USA). The same set of tumors was used to corroborate the results with realtime quantitative reverse transcriptionYpolymerase chain reaction (RT-qPCR) and with immunohistochemistry.
RNA Extraction
Total RNA was purified using RNeasy spin columns (Qiagen, Valencia, CA, USA) according to the manufacturer's protocol. Quantification and quality assessment of the RNA were performed using Agilent 2100 Bioanalyzer and RNA Pico Kit (Agilent Technologies, Santa Clara, CA, USA). All samples yielded clean and undegraded RNA based on the appearance of electropherograms and RNA integrity numbers greater than 7. The RNA was reverse-transcribed with Taqman Reverse Transcription Reagents kit (Applied Biosystems, Foster City, CA, USA), twice amplified, labeled (Life Sciences, Inc., Farmingdale, NY, USA) and submitted to the Massachusetts General Hospital microarray core facility (Charlestown, MA, USA).
Microarray Processing and Analysis
Complementary deoxyribonucleic acid (DNA) was transformed into messenger ribonucleic acid (mRNA) and biotin labeled with the BioArray High Yield RNA Transcript Labeling Kit (Affymetrix). The hybridization of the fragmented biotinlabeled mRNA to the Human X3P GeneChip (Affymetrix), which screens 47,000 transcripts with 61,000 probe sets, and scanning of the chip was performed according to the manufacturer's protocol in the microarray core facility. Microarray data were analyzed using GenePattern 3.0 platform (Broad Institute, Cambridge, MA, USA) (7) as previously described (8) . Class neighbors analysis (9) and comparative marker selection (10) were used to determine which genes best characterize a patient group whereas knowing a priori whether a sample belonged to a good or a poor hearing group. Genes were ranked using the t test statistic. The false discovery rate (FDR) statistic was set to less than 10% to adjust for multiple hypothesis testing whereas estimating probabilities that differences in gene expression represent false-positive findings.
Gene set enrichment analysis (GSEA) (11) was used to determine subtle but coordinated differences in expression of previously defined sets of genes. The analyzed gene sets included the cytogenetic set that contains 386 gene sets corresponding to cytogenetic bands, the functional set that contains 1687 gene sets involved in specific metabolic and signaling pathways, the neighborhood set that contains 427 gene sets defined by expression neighborhood centered on cancer-related genes, and a regulatory motif set that contains 837 gene sets with commonly conserved regulatory motifs in the promoter regions. Correction for multiple hypotheses testing and gene set size was automatically implemented using sample permutations. Gene sets that contained fewer than 25 genes and more than 500 genes were ignored, which is appropriate for data sets with more than 10,000 features (11) . We focused on gene sets with an FDR of less than 10% because they are most likely to generate interesting hypotheses and drive further research.
Real-Time RT-qPCR
Real-time RT-qPCR was used to validate the expression of 7 genes selected from microarray analyses. Real-time RT-qPCR was carried on all but 1 sample of RNA used for microarray analyses (Sample No. 3769; Table 1 ) because there was not enough RNA to perform the analysis from that sample. For the selected genes, 6-FAM linked fluorescent probes and primers were designed and optimized by Applied Biosystems. The measurements were performed on an Applied Biosystems 7700 Sequence Detection System using 96-well plates and conditions as previously described (8) . Statistical significance of the measurements was determined using the bootstrap resampling method (12) with the threshold set to p G 0.05.
Immunohistochemistry
Immunohistochemistry was performed on 8-Km sections of formalin-fixed, paraffin-embedded representative samples from the same frozen tumors used for the microarray analyses. Sections were immunostained using primary monoclonal antibody against neurofilament (Nf, Catalog No. M0762, clone 2F11; DAKO, Fort Collins, CO, USA), polyclonal antibody against Rad45B (Catalog No. LS-C9872/L7101868; Lifespan Biosciences, Seattle, WA, USA), polyclonal antibody against platelet factor 4 (Pf4, Catalog No. 500-P05; PeproTech, Inc., Rocky Hill, NJ, USA), and polyclonal antibody against carcinoembryonic antigen (CEA, Catalog No. 7602507; Ventana Medical, Tucson, AZ, USA). Antigen retrieval techniques 
Statistical Analysis
Exact nonparametric tests were used to assess association between good versus poor hearing and tumor histologic diagnosis and patient demographics. The two-sided Fisher exact test was used to assess whether sex, size, histological, and immunohistochemical features of the tumors are differently distributed between the 2 hearing groups. The Wilcoxon rank-sum test was used to assess the relationship between hearing and age. Owing to the small sample size, the formal statistical analyses are exploratory, and we did not apply corrections for multiple comparisons in the analyses of the clinical data.
RESULTS
In the patients we studied, hearing was independent of age ( p = 0.27), sex ( p = 0.1), tumor size ( p = 0.56), vessel density ( p = 1.00), and fat content of tumors ( p = 1.00). Of 47,000 transcripts assayed with the microarrays, 5,767 were at least 2-fold increased and 2,567 were at least 2-fold decreased in tumors associated with poor hearing. A scatter plot of the fold difference in expression and the associated p values for all transcripts is shown in Figure 1 . None of the genes met the criterion for a statistically significant difference in expression when accounting for multiple comparisons implicit in microarray data. Nonetheless, the microarray data pointed to trends in differential gene expression, as depicted in the heat map shown in Figure 2 .
To determine whether the trends observed in the microarray data are relevant, we verified with RT-qPCR expression of 5 genes with substantial, albeit not statistically significant, difference in expression between the 2 groups. These genes included PF4 whose expression was higher in samples with poor than good hearing, and 4 genes whose expression was lower in samples with poor hearing: long chain acyl-coA synthetase 2 (LACS2), lysyl oxidase (LOX), RAD54 homolog B (RAD54B), and prostate-specific membrane antigenYlike (PSMAL). The results are summarized in Figure 3 and Table 2 . This table shows that the RT-qPCR data were in overall good agreement with the microarray data, although the magnitude of the divergence between the groups differed somewhat between the 2 techniques. Moreover, by virtue of testing few genes, RT-qPCR was more sensitive than microarrays in detecting statistically significant differences in gene expression from a relatively small number of samples. Two genes, PSMAL and RAD54B, met the statistical criterion for decreased expression in tumors associated with poor hearing.
In addition to analyzing individual genes, GSEA was used to test whether sets of related genes were systematically altered between the 2 groups. A cytogenetic gene set within the chromosomal band 3q27 was found to be most significantly different (FDR G10%) between the 2 groups suggesting that regional effects within that chromosomal band affect hearing. No gene sets were enriched within the functional, neighborhood, or regulatory motif sets. The 3q27 band includes 87 genes, pseudogenes, and loci. Within 3q27, we selected genes that have known roles in hearing or encode secreted proteins and whose microarray-assayed expression was at lest 2.5-fold different between the 2 groups. Two genes met these criteria, namely, peroxisomal biogenesis factor 5Ylike (PEX5L) and guanine nucleotide binding protein beta polypeptide 4 (GNB4), and were validated with RTqPCR. As summarized in Table 2 and Figure 3 , the expression of PEX5L but not GNB4 was significantly different between the 2 groups with PEX5L being 23.4 T 20 less expressed in tumors associated with poor hearing.
Immunohistochemistry was used to verify RT-qPCR data at the protein level, to determine cellular localization of the gene products of interest, and to test mechanistic hypotheses. The results are summarized in Table 3 . Vestibular schwannomas consist of nonmyelinating tumor cells (13) . Using antibodies against neurofilament, we evaluated the hypothesis that higher levels of peroxisomal gene PEX5L in tumors with good hearing reflect the presence of functional, myelinated axons within these tumors. Although axons could be observed within (Bintratumoral distribution[) or at the periphery (Bperipheral distribution[) of some tumors, there was no correlation between the presence of axons and the preservation of hearing ( p = 0.56). Peroxisomal disorders can also be associated with pathologic accumulation of fat (14) but we found no correlation between the presence of fat within the tumors and the severity of HL ( p = 1.00).
Although RT-qPCR did not detect statistically significant difference in expression of PF4, we pursued the gene product with immunohistochemistry because PF4 had a tendency for increased expression in tumors associated with poor hearing, and it encodes a secreted protein. A majority of the tumors (4/4 in the poor hearing and 7/9 in the good hearing group) were positive for Pf4 but there was no correlation between HL and cellular distribution of Pf4 ( p = 1.00); exclusively perivascular or diffuse pattern was noted in both groups. We also semiquantitatively evaluated the number of blood vessels in tumors because Pf4 is a negative regulator of angiogenesis (15) . We found no correlation between vessel density in tumors and HL ( p = 1.00). There was a tendency for a correlation between vessel density and tumor size: 3 of 8 large tumors (92.5 cm) and none of the small tumors had many blood vessels, whereas 4 of 6 small tumors and only 1 large tumor had rare vessels; these differences were not statistically significant. Cellular expression of Rad54B, a member of the complex involved in the recombinational repair of DNA Immunostaining for Nf, Pf4, and Rad54B and is classified by the site of distribution and the intensity of staining where 0 = no staining, 1 = intense staining, 2 = very intense staining. An additional category of 3 = extremely intense staining was used for CEA. The category Bfat[ is classified as absent (0) or present (1) . The category Bvessels[ indicates whether no (0), some (1), or many (2) vessels were noted. Highlighted samples are from the poor hearing group. damage, appeared to differ in the 2 groups of tumors. Cytoplasmic staining (without nuclear staining) was noted in 2 of 4 tumors associated with poor hearing and in no tumors associated with good hearing. The reverse pattern of nuclear staining (but no cytoplasmic staining, or with nuclear staining more intense than cytoplasmic staining) was observed in 2 tumors associated with good hearing but in no tumors associated with poor hearing. However, these differences did not meet statistical criteria for significance ( p = 0.69 for nuclear Rad54B and p = 0.77 for cytoplasmic Rad54B). There was a significant correlation between the presence of nuclear Rad54B staining and the absence of neurofilament staining ( p = 0.04). Both groups included tumors with equal or no staining in either the cytoplasm or the nucleus. The final gene that we studied is CEA-related cell adhesion molecule 7 (CEACAM7) because of its higher expression in tumors associated with poor hearing (Fig. 2) . This gene belongs to the family that includes CEA (also known as CEACAM5)Va widely used tumor marker in serum immunoassay determinations of carcinomas. Immunostaining for CEA corroborated the transcriptional data: higher levels of CEA were found in tumors associated with poor hearing (Fig. 4) . Two of 4 tumors with poor hearing and only 1 of 9 tumors with good hearing expressed CEA abundantly (Fig. 4A) . Most of the tumors associated with good hearing expressed CEA at very low levels (Fig. 4B ). These differences were not statistically significant ( p = 0.20). Nonetheless, the observed trends cannot be attributed to known benign conditions that can elevate serum CEA levels such as smoking, infections, pancreatitis, or cirrhosis (16) because none of the patients in the study experienced these conditions.
DISCUSSION
Although several reports have described the use of expression microarrays to examine VSs (5,6), this study is the first to screen the entire human genome for alterations in gene expression that could account for differences in HL associated with VSs. Despite the limited sample size and significant intersample variability, this study has identified several possibly relevant genes by validating microarray data with 2 complementary techniquesVRTqPCR and immunohistochemistry. Four genes seem to be strongly associated with HL, namely, PEX5L, RAD54B, PSMAL, and CEA. None of these genes have been previously reported in association with VSs or normal vestibulocochlear nerve.
Peroxisome biogenesis factor 5Ylike gene is mostly expressed in the brain, and it is thought to regulate peroxisomal protein import (17) . Peroxisomes are ubiquitous organelles that participate in the metabolism of fatty acids and other metabolites. Although baseline expression of PEX5L in normal vestibular or cochlear nerve has not been reported, current data suggest that peroxisomal dysfunction contributes to HL based on differentially decreased expression of PEX5L in VSs associated with poor hearing. Peroxisomal dysfunction may manifest as pathologic accumulation of fat and/or demyelination and neurodegeneration in the adjacent acoustic nerve (14) . Neither of these mechanisms could be definitively supported by the current data, leaving the possibility that novel pathologic mechanisms are at play or that altered PEX5L expression in VSs is an epiphenomenon. Future studies in a larger study set may be able to delineate these possibilities. Nonetheless, the hypothesis that peroxisomal dysfunction and demyelination contribute to HL associated with VSs, through as of yet unidentified mechanisms, is intriguing for several reasons. First, both peroxisomal disorders (14) and hereditary myelopathies (18Y20) lead to the type of HL that is characteristic of VSsVprogressive sensorineural HL with decreased ability to discriminate speech, which is typically significantly worse than anticipated from the ability to detect pure tones. Second, VSs have been suggested to cause demyelination of the vestibular nerve based on the analysis of hyperventilation-induced nystagmus in patients with VSs (21) . Third, histological analyses of VSs and the associated nerve have reported demyelinating changes in the nerve (22, 23) .
The 3q27 chromosomal region that includes PEX5L has not been previously implicated in tumorigenesis of sporadic VSs (24, 25) . However, the GSEA from this study suggests that regional alterations within 3q27, including chromosomal deletions or amplifications, dosage compensation, and epigenetic silencing, may contribute to the difference in HL associated with VSs. Given that GSEA optimization is sensitive to initialization, future studies with more samples may be able to increase the accuracy of GSEA.
Another gene found to be expressed at lower levels in VSs associated with poor hearing than good hearing is RAD54B. This gene is part of a complex involved in the recombinational repair of DNA damage. Mutations in RAD54B have been identified in nonYHodgkin lymphoma and colon cancer (26) , whereas RAD51, which interacts with RAD54B, has been associated with breast tumorYsusceptibility genes (27) . The tendency for preferential cytoplasmic distribution of Rad54B in VSs associated with good hearing and nuclear distribution in VSs associated with poor hearing suggests different abilities to respond to DNA damage. In other systems, Rad54 has been detected in the cytoplasm (28) and it moves to the nucleus after DNA damage to assist with DNA repair (26) . Similarly, Rad51 can be detected in the cytoplasm (29) , although it is reported to be a nuclear protein (30) . Multiple functions for cytoplasmic Rad51 have been proposed: further processing of DNA that underwent repair in the nucleus, termination of recombination repair initiated in the nucleus, indication of early stages of cell death, or as yet unidentified function (29) . It remains to be investigated how putative impaired ability to repair DNA damage in VSs associated with poor hearing contributes to HL. Furthermore, the absence of any immunoreactivity in some tumors despite the presence of RAD54B mRNA suggests impaired translation to a functional protein, which may be compensated by upregulation of other genes involved in DNA repair.
A final gene expressed at substantially lower levels in VSs associated with poor hearing than good hearing is PSMAL also known as glutamate carboxypeptidase III. Although PSMAL is expressed at high levels in the brain (31) , biological significance of PSMAL is not yet known (32) . However, PSMAL is 98% homologous to prostatespecific membrane antigen whose inhibition has been shown to be neuroprotecitive in animal models of stroke, neuropathic pain, and other neurodegeneration (33, 34) .
In contrast to the 3 genes discussed thus far, CEA-CAM7 gene and CEA protein were expressed at higher levels in tumors associated with poor hearing. CEA is a glycoprotein whose elevated levels in the serum and cerebrospinal fluid (CSF) are frequently associated with epithelial malignancies and metastases to the central nervous system (35Y37). In addition, elevated CSF levels of CEA have been found in primary malignant (36) or benign (38) lesions of the central nervous system. Interestingly, elevated CEA in CSF has been associated with HL (38Y42), and normalization of CEA levels using intrathecal methotraxate for treatment of leptomeningeal carcinomatosis leads to improvement in hearing (41) . Our findings suggest that CEA may contribute to HL associated with VSs through as of yet unidentified mechanisms.
There may be a link between putative peroxisomal dysfunction and altered CEA levels in VSs associated with poor hearing because activation of the nuclear hormone peroxisome proliferatorYactivated receptor gamma induces CEA (43) . The other 2 genes identified in this study (RAD54B and PSMAL) may play indirect roles in causing degeneration of the inner ear rather than by secreting a toxic substance. Such indirect roles include, and are not limited to, decreased production or decreased responsiveness to putative factors required for normal function of the auditory nerve and the inner ear. More data are needed to delineate these mechanistic possibilities.
Our finding suggesting that tumor size is positively correlated with vessel density is consistent with a previous report that tumor size and clinical growth index are proportional to the total number of vessels (44) .
CONCLUSION
Progressive sensorineural HL associated with VSs is a major clinical problem for which curative therapies are lacking and molecular pathogenesis remains elusive. The use of high-throughput microarray technology validated by RT-qPCR and immunohistochemistry has led to the identification of 4 genes (PEX5L, RAD54B, PSMAL, and CEA) as possible determinants of HL associated with VSs. These findings need to be verified on large and independent data sets in the future. Nonetheless, the identified genes are potential therapeutic targets to prevent or reduce HL associated with VSs.
